Biblioteca | | Page 11

Type 2M and Type 2A von Willebrand Disease: Similar but Different

someth1 mes desde que se envió1 mes desde que se envió01 minutos

Descarga: Type 2M and Type 2A von Willebrand Disease: Similar but Different Archivo: eha/vonwill/STH 2016 2M vs 2A VWD.pdf Analogous to the differentiation between hemophilia A and B, respectively, reﬂecting deﬁciency in factor VIII (FVIII) and FIX, and increasing being recognized as reﬂecting clinicallydifferentdisorders,types2Aand2MvonWillebranddisease(VWD)canalsobe shown to express both similarities and differences in their prevalence, genetic…

Individualized antithrombotic therapy

someth1 mes desde que se envió1 mes desde que se envió05 minutos

Descarga: Individualized antithrombotic therapy Archivo: tromboembolia-venosa/haemo 2016 individualized antithrombotic therapy.pdf Clot formation in the circulation is a physiological mechanism preventing bleeding at sites of loss of vascular integrity. Clot formation may also occur intravascularly under pathological conditions, e. g. leading to myocardial infarction, stroke, and critical limb ischaemia. Clot formation involves activation of the coagulation…

Newlocations of intravascular tissue factor

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Newlocations of intravascular tissue factor Archivo: tromboembolia-venosa/tvp/haemo_2007-New locations of intravascular tissue factor .pdf Tissue factor (TF) is the major initiator of blood coagulation, and a mediator of inflammation, angiogenesis, and carcinogenesis. According to recent evidence, preformed TF and inducible expression of the protein is observed in several blood components. TF is apparently constitutively expressed…

Oral anticoagulation with edoxaban

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Oral anticoagulation with edoxaban Archivo: tromboembolia-venosa/haemo_2012-oral anticoagulation with edoxabanpdf.pdf Edoxaban (the former DU176b) an orally available direct factor Xa inhibitor has been engineered from DX-9065a, which was one of the first parenteral Xa inhibitors. Edoxaban has a time to peak plasma concentrations of 1–2 hours and a half-life of approximately 10 hours after multiple…

Biomarkers for arterial and venous thrombotic disorders

someth1 mes desde que se envió1 mes desde que se envió03 minutos

Descarga: Biomarkers for arterial and venous thrombotic disorders Archivo: tromboembolia-venosa/haemo_2014-Biomarkers for arterial and venous thrombotic disorders.pdf The haemostatic system maintains the blood in a fluid state, but allows rapid clot formation at sites of vascular injury to prevent excessive bleeding. Unbalances within the haemostatic system can lead to thrombosis. Inspite of successful research our understanding…

Biomarkers for arterial and venous thrombotic disorders

someth1 mes desde que se envió1 mes desde que se envió03 minutos

Descarga: Biomarkers for arterial and venous thrombotic disorders Archivo: tromboembolia-venosa/haemo_2014-Biomarkers for arterial and venous thrombotic disorders.pdf The haemostatic system maintains the blood in a fluid state, but allows rapid clot formation at sites of vascular injury to prevent excessive bleeding. Unbalances within the haemostatic system can lead to thrombosis. Inspite of successful research our understanding…

Comparative genetics of warfarin resistance

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Comparative genetics of warfarin resistance Archivo: tromboembolia-venosa/haemo_2014-Comparative genetics of warfarin resistance.pdf Warfarin and other 4-hydroxycoumarinbased oral anticoagulants targeting vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) are administered to humans, mice and rats with different purposes in mind – to act as pesticides in high-dosage baits for killing rodents, but also to save lives…

El Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT). Historia y perspectiva

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: El Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT). Historia y perspectiva Archivo: historia/Historia del Claht.pdf El Grupo Cooperativo Latinoamericano de Hemostasia y Trombosis (CLAHT) lo fundaron, oﬁcialmente, en 1976, varios profesionales expertos en hemostasia y trombosis. Este grupo se conformó como parte de las actividades académicas de la International Society of Hematology (ISH)…

Management of bleeding with oral anticoagulants in patients with atrial fibrillation

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Management of bleeding with oral anticoagulants in patients with atrial fibrillation Archivo: tromboembolia-venosa/tvp/haemo_2015-Management of bleeding with oral anticoagulants in.pdf Fear of bleeding is a common barrier to the use of anticoagulants. Warfarin has been the only oral anticoagulant for more than 60 years and warfarin-related bleeding is reported to be the most common drug-related…

Monocyte subsets in atherosclerosis

someth1 mes desde que se envió1 mes desde que se envió01 minutos

Descarga: Monocyte subsets in atherosclerosis Archivo: tromboembolia-venosa/tvp/haemo_2015-monocyte in atherosclerosis.pdf Endothelial dysfunction and chronic inflammation of the arterial wall continuously drive the development of atherosclerotic lesions. Monocytes, as cells of the innate immunity, are particularly involved in this process. In the last decade, heterogeneity of circulating monocytes has widely been acknowledged, and a recent consensus nomenclature…